Combination therapies targeting multiple pathways, such as DNA-damaging agents and BRAF inhibitors, have demonstrated enhanced tumor cell death both in vitro and in vivo, while also preventing melanoma re-growth after treatment discontinuation [19]. This evidence concerns the gene BRAF and melanoma.